» Authors » Elena Hernandez-Encinas

Elena Hernandez-Encinas

Explore the profile of Elena Hernandez-Encinas including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 11
Citations 331
Followers 0
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
1.
Zhu L, Retana D, Garcia-Gomez P, Alvaro-Espinosa L, Priego N, Masmudi-Martin M, et al.
EMBO Mol Med . 2022 Feb; 14(3):e14552. PMID: 35174975
We report a medium-throughput drug-screening platform (METPlatform) based on organotypic cultures that allows to evaluate inhibitors against metastases growing in situ. By applying this approach to the unmet clinical need...
2.
Cash T, Alcala S, Rico-Ferreira M, Hernandez-Encinas E, Garcia J, Albarran M, et al.
Cancers (Basel) . 2020 Jul; 12(7). PMID: 32635473
Despite significant efforts to improve pancreatic ductal adenocarcinoma (PDAC) clinical outcomes, overall survival remains dismal. The poor response to current therapies is partly due to the existence of pancreatic cancer...
3.
Ferrara-Romeo I, Martinez P, Saraswati S, Whittemore K, Grana-Castro O, Thelma Poluha L, et al.
Nat Commun . 2020 Mar; 11(1):1168. PMID: 32127537
Telomerase deficiency leads to age-related diseases and shorter lifespans. Inhibition of the mechanistic target of rapamycin (mTOR) delays aging and age-related pathologies. Here, we show that telomerase deficient mice with...
4.
Llanos S, Megias D, Blanco-Aparicio C, Hernandez-Encinas E, Rovira M, Pietrocola F, et al.
Oncogene . 2019 Jan; 38(20):3886-3902. PMID: 30692638
Palbociclib is a selective inhibitor of cyclin-dependent kinases 4 and 6 (CDK4/6) approved for the treatment of some cancers. The main mechanism of action of palbociclib is to induce cell...
5.
Priego N, Zhu L, Monteiro C, Mulders M, Wasilewski D, Bindeman W, et al.
Nat Med . 2018 Jun; 24(9):1481. PMID: 29921958
In the version of this article originally published, the names of three authors were incorrect. The authors were listed as "Coral Fustero-Torres", "Elena Pineiro" and "Melchor Sánchez-Martínez". Their respective names...
6.
Priego N, Zhu L, Monteiro C, Mulders M, Wasilewski D, Bindeman W, et al.
Nat Med . 2018 Jun; 24(7):1024-1035. PMID: 29892069
The brain microenvironment imposes a particularly intense selective pressure on metastasis-initiating cells, but successful metastases bypass this control through mechanisms that are poorly understood. Reactive astrocytes are key components of...
7.
Morales-Garcia J, Gine E, Hernandez-Encinas E, Aguilar-Morante D, Sierra-Magro A, Sanz-SanCristobal M, et al.
Sci Rep . 2017 Oct; 7(1):13526. PMID: 29051532
The CCAAT/Enhancer binding protein β (C/EBPβ) is a transcription factor involved in numerous physiological as well as pathological conditions in the brain. However, little is known regarding its possible role...
8.
Martinez Gonzalez S, Hernandez A, Alvarez R, Rodriguez A, Ramos-Lima F, Bischoff J, et al.
Bioorg Med Chem Lett . 2017 Oct; 27(21):4794-4799. PMID: 29017786
A scaffold hopping strategy, including intellectual property availability assessment, was successfully applied for the discovery of novel PI3K inhibitors. Compounds were designed based on the chemical structure of the lead...
9.
Hernandez-Encinas E, Aguilar-Morante D, Morales-Garcia J, Gine E, Sanz-SanCristobal M, Santos A, et al.
J Neuroinflammation . 2016 Oct; 13(1):276. PMID: 27769255
Background: The CCAAT/enhancer-binding protein β (C/EBPβ) is a transcription factor implicated in the control of proliferation, differentiation, and inflammatory processes mainly in adipose tissue and liver; although more recent results...
10.
Hernandez-Encinas E, Aguilar-Morante D, Cortes-Canteli M, Morales-Garcia J, Gine E, Santos A, et al.
J Neuroinflammation . 2015 Jan; 12:14. PMID: 25617152
Background: The CCAAT/enhancer-binding protein β (C/EBPβ) is a transcription factor, which was first identified as a regulator of differentiation and inflammatory processes mainly in adipose tissue and liver; however, its...